TrialVascular health and risk management2014

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.

A John Camm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.